The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patients—Single institution experience.
Angela Moliterni
No relevant relationships to disclose
Gabriella Mariani
No relevant relationships to disclose
Giulia Carlo Stella
No relevant relationships to disclose
Luigi Mariani
No relevant relationships to disclose
Giulia Valeria Bianchi
No relevant relationships to disclose
Giuseppe Capri
No relevant relationships to disclose
Sara Cresta
No relevant relationships to disclose
Paola Mariani
No relevant relationships to disclose
Silvia Damian
No relevant relationships to disclose
Elena De Benedictis
No relevant relationships to disclose
Francesco Gelsomino
No relevant relationships to disclose
Elisa Zanardi
No relevant relationships to disclose
Matteo Duca
No relevant relationships to disclose
Lorenzo Sica
No relevant relationships to disclose
Anna Tessari
No relevant relationships to disclose
Filippo G. De Braud
Consultant or Advisory Role - Novartis (U); Philogen (U); Pierre Fabre Medicament (U); Roche (U); SERVIER (U)